Coles S K, Ernsberger P, Dick T E
Department of Anatomy, Division of Pulmonary and Critical Care Medicine, Case Western University, 11100 Euclid Avenue, Cleveland, OH 44106-4941, USA.
Brain Res. 1998 Jun 1;794(2):267-73. doi: 10.1016/s0006-8993(98)00234-0.
The aim of this study was to determine whether post-hypoxic frequency decline (PHFD) requires central activation of alpha2-adrenergic receptors. PHFD is defined as the undershoot in respiratory frequency that occurs immediately following brief hypoxic periods. Adult anesthetized, vagotomized rats were exposed to hypoxia (8% O2, mean=45 s) before and after intracerebroventricular (i.c.v.) infusion of vehicle or alpha2-antagonist. The efficacy of the i.c.v. antagonist was assessed by recording the response to intravenous injection of alpha2-agonist before and after the infusion. We compared breathing frequencies before, during, and after hypoxia, both before and after treatments. The decline in breathing frequency after hypoxia was not prevented by the alpha2-antagonists, RX 821002 or SK&F-86466. Guanabenz, an alpha2-agonist, prolonged baseline expiration and potentiated PHFD. Prior treatment with SK&F-86466 blocked the agonist-evoked response which was also reversed by subsequent administration of SK&F-86466. We conclude that PHFD does not require the activation of alpha2-adrenergic receptors, but that alpha2-adrenergic receptors can modulate resting and post-hypoxic respiratory frequency.
本研究的目的是确定低氧后频率下降(PHFD)是否需要α2 - 肾上腺素能受体的中枢激活。PHFD被定义为在短暂低氧期后立即出现的呼吸频率下冲。成年麻醉、迷走神经切断的大鼠在脑室内(i.c.v.)注入载体或α2拮抗剂之前和之后暴露于低氧环境(8% O2,平均 = 45秒)。通过记录注入前后静脉注射α2激动剂的反应来评估i.c.v.拮抗剂的效果。我们比较了治疗前后低氧期间及低氧前后的呼吸频率。α2拮抗剂RX 821002或SK&F - 86466并不能阻止低氧后呼吸频率的下降。α2激动剂胍那苄延长了基线呼气并增强了PHFD。预先用SK&F - 86466治疗可阻断激动剂诱发的反应,随后再次给予SK&F - 86466也可逆转该反应。我们得出结论,PHFD不需要α2 - 肾上腺素能受体的激活,但α2 - 肾上腺素能受体可以调节静息和低氧后的呼吸频率。